Botanix Pharmaceuticals fully funded to complete phase 2 atopic dermatitis trial

Botanix Pharmaceuticals ASX BOT funded complete atopic dermatitis trial
There is currently no effective treatment for atopic dermatitis and Botanix claims its BTX 1204 has strong potential.

Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) has raised A$8 million through an oversubscribed placement to professional, institutional and sophisticated investors across Australia and Asia.

The raising comes at a critical juncture in the company’s development as it looks to conduct a series of highly anticipated clinical trials commencing next month.

Botanix said that the funds generated will be used to “rapidly advance” BTX 1204 into a phase 2 clinical trial. The phase 2 trial is expected to cost around A$6 million and if successful,

... read more at: